DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vaniqa (Eflornithine Hydrochloride) - Published Studies

 
 



Vaniqa Related Published Studies

Well-designed clinical trials related to Vaniqa (Eflornithine)

Topical eflornithine hydrochloride improves the effectiveness of standard laser hair removal for treating pseudofolliculitis barbae: a randomized, double-blinded, placebo-controlled trial. [2012]

Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. [2010.10.06]

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. [2009.07.04]

Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. [2007.12.01]

A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. [2007.07]

The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness. [2004.06]

Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. [2000]

Eflornithine versus cotrimoxazole in the treatment of Pneumocystis carinii pneumonia in AIDS patients. [1992.12]

Treatment of recurrent gliomas with eflornithine. [1992.09.16]

Well-designed clinical trials possibly related to Vaniqa (Eflornithine)

Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. [2010.09]

Chemotherapy for second-stage Human African trypanosomiasis. [2010.08.04]

A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. [2010.01]

Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. [2010]

A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. [2010]

Chemopreventive efficacy of topical difluoromethylornithine and/or triamcinolone in the treatment of actinic keratoses analyzed by karyometry. [2009.12]

Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. [2009.03]

Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. [2009.03]

Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. [2008.06]

Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. [2008.06]

The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. [2008.02]

Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. [2007.08]

Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. [2006.08]

Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer. [2005.11]

Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. [2005.01.01]

Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. [2003.03]

A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. [2002.10]

Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. [2002.01]

Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. [2001.06]

Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions. [2001.05]

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. [2001.01.01]

Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. [2000.12]

Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. [2000.10]

Incidence of BRCA1/2 germ line alterations in a high risk cohort participating in a phase II chemoprevention trial. [2000.06]

Bayesian monitoring of phase II trials in cancer chemoprevention. [1999.08]

A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. [1998.11]

Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine. [1998.10]

Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. [1998.08.19]

alpha-difluoromethylornithine ototoxicity. Chemoprevention clinical trial results. [1997.12]

Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. [1996.05]

Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer. [1995]

Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. [1993.05.05]

Urinary polyamine levels in cancer patients treated with D,L-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis. [1989.07]

Other research related to Vaniqa (Eflornithine)

A molecular mechanism for eflornithine resistance in African trypanosomes. [2010.11.24]

Ornithine Decarboxylase-1 Polymorphism, Chemoprevention With Eflornithine and Sulindac, and Outcomes Among Colorectal Adenoma Patients. [2010.08.26]

Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. [2010]

Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. [2009.03]

The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain. [2008.11]

Enantioselective and nonlinear intestinal absorption of eflornithine in the rat. [2008.08]

Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. [2008.03.29]

Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. [2008.02]

A 4-month, open-label study evaluating the efficacy of eflornithine 11.5% cream in the treatment of unwanted facial hair in women using TrichoScan. [2008.01]

Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series. [2007.11.07]

The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism. [2007.09]

A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. [2007.01.29]

Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. [2006.10]

Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. [2006.10]

Excess salt and pepper hair treated with a combination of laser hair removal and topical eflornithine HCl. [2006.06]

Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. [2005.09.01]

Eflornithine for the treatment of human African trypanosomiasis. [2003.06]

Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis. [2002.09]

Percutaneous absorption and pharmacokinetics of eflornithine HCl 13.9% cream in women with unwanted facial hair. [2001.09]

Vaniqa--eflornithine 13.9% cream. [2001.04]

Topical eflornithine. [2001]

Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair. [2001]

Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma. [1998.01]

The role of the polyamine inhibitor eflornithine in the neuropathogenesis of experimental murine African trypanosomiasis. [1997.06]

A seven days course of eflornithine for relapsing Trypanosoma brucei gambiense sleeping sickness. [1997.03]

Eflornithine treatment in SHR: potential role of vascular polyamines and ornithine decarboxylase in hypertension. [1994.09]

Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. [1993.07]

Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. [1992.09.12]

Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. [1992.01]

Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy. [1990.10]

Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. [1990.09]

In vivo effect of eflornithine (DFMO) and some related compounds on Leishmania infantum preliminary communication. [1989.12]

Eflornithine. A new drug in the treatment of sleeping sickness. [1989.06.23]

[African trypanosomiasis in children treated with eflornithine. A case] [1989.06.17]

[A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo] [1989.04]

Intestinal crytosporidiosis treated with eflornithine: a prospective study among patients with AIDS. [1989]

Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review. [1989]

African sleeping sickness in the United States. Successful treatment with eflornithine. [1988.02]

Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Cote d'Ivoire. [1987.11]

Treatment of acute myeloid leukemia and blastic phase of chronic myeloid leukemia with combined eflornithine (alpha difluoromethylornithine) and methylglyoxal-bis-guanyl hydrazone (methyl-GAG). [1987]

Other possibly related research studies

Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells. [2005]

Suppression and regression of choroidal neovascularization by polyamine analogues. [2005.09]

Karyometry in the early detection and chemoprevention of intraepithelial lesions. [2005.09]

Guidance for the management of hirsutism. [2005.08]

Ornithine decarboxylase, mitogen-activated protein kinase and matrix metalloproteinase-2 expressions in human colon tumors. [2005.05.28]

Polyamine depletion inhibits irradiation-induced apoptosis in intestinal epithelia. [2005.09]

Albumin stimulates cell growth, l-arginine transport, and metabolism to polyamines in human proximal tubular cells. [2005.05]

Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? [2005.02]

The role of polyamines in human cancer: prospects for drug combination therapies. [2004.12]

Lung distribution of the chemopreventive agent difluoromethylornithine (DFMO) following oral and inhalation delivery. [2004.12]

Cellular mechanisms mediating the anti-invasive properties of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) in human breast cancer cells. [2004]

Polyamines and cancer: old molecules, new understanding. [2004.10]

Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine. [2004.11]

Inhibitors of polyamine metabolism: review article. [2004.07]

Protective role of arginase in a mouse model of colitis. [2004.08.01]

Irreversible ototoxicity associated with difluoromethylornithine. [2004.07]

Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. [2004.10]

Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. [2004]

Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies. [2004.06]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017